Thursday, August 23, 2012

Ocular Therapeutix Tear Duct Plug Trial Reaches Phase II

Ocular Therapeutix may have found a new way to increase patient compliance via tiny hydrogel plugs.  The phase II trial for patients being treated with ocular hypertension and glaucoma will be conducted in South Africa and enroll 20 patients. These tiny degradable tear drainage ducts deliver medication directly to the eye over the course of several months. This will ultimately eliminate the inconvenience of daily drops.  

At Drug Delivery Partnerships, dozens of established and novel drug delivery technology companies like Ocular Therapeutix join hundreds of pharmaceutical and drug delivery thought leaders to develop partnerships to create the next great product that will bring relief to millions of patients. Sign up for updates on the 17th Annual Drug Delivery Partnerships Conference taking place February 6-8, 2012, in San Diego, CA.

No comments:

Post a Comment